Explore the Knowledge Graph

Diseases

Every condition and disease as data, in the vocabulary your systems already use

Coverage

  • Every condition on a label or in a trial. 141,000+ conditions in all.
  • Mapped to the standard ontologies: UMLS, SNOMED CT, MedDRA, MeSH, and ICD-10.
  • Built into a hierarchy. Synonyms and alternate names resolve to one condition, which sits under its parents and above its subtypes.
  • Every use and exclusion: 21,800+ indications and 9,900+ contraindications, each with its own region, route, and age group; 1,300+ off-label, and 6,000+ conditions flagged rare.

Where it connects

Condition record Duchenne Muscular Dystrophy (DMD) DBCOND0040032 condition · rare disease
Drugs Every drug with an indication recorded on the condition
nameAtaluren drugbank_idDB05016 approval_statusapproved, withdrawn modalitySmall molecule kindmanagement_of countryEU off_labelfalse +8 more drugs
Targets The targets of the drugs indicated for it
biodb_nameDystrophin uniprot_idP11532 ttd_strength_of_evidencePhase 2; Phase 2/3; Approved ot_score0.8429 combined_score1.5929 +1,796 more proteins
Clinical trials Trials with the condition on their record, and what phase each is at
NCT05126758 NCT05524883 NCT05540860 NCT05558813 NCT05689164 NCT05933057 NCT05938023 +244 more
NCT05933057.statusrecruiting NCT05689164.statusterminated NCT05558813.statuswithdrawn NCT05558813.phases[]
Companies Sponsors of those trials, resolved to the parent company

Via a registered trial

trialNCT05689164 sponsor.title (as filed)Pfizer agency_classindustry sponsor_company.name (resolved)Pfizer +71 more industry sponsors

Via a preclinical program

programDBPRG00151626 raw_phaseIND-enabling company.name (resolved)Dyne Therapeutics +205 more programs

Zoom in

DMD indications, by drug
drugdrug_drugbank_idkindcountryroutedose_formage_groups
Delandistrogene moxeparvovecDB16802treatment_ofUSIntravenousKitpediatric
GivinostatDB12645treatment_ofUSOralSuspension[]
CasimersenDB14984treatment_ofUSIntravenousInjection[]
EteplirsenDB06014management_ofUSIntravenousInjection[]
VamoroloneDB15114management_ofEUOralSuspension[]
AtalurenDB05016management_ofEU[][][]

+4 more indications

DMD ontology codes
identifier_typeidentifiertitle
MedDRAllt/10013801Duchenne muscular dystrophy
MedDRApt/10059117Becker's muscular dystrophy
MeSHt/T811507Muscular Dystrophy, Duchenne Type
MeSHc/M0583499Duchenne and Becker Muscular Dystrophy
SNOMED CTc/76670001null
UMLScui/C0013264null
ICD-10c/G71.01null

+39 more codes

Drugs contraindicated in Severe Hepatic Impairment (DBCOND0070791)
drugdrug_drugbank_idrelationshipregionroute
TegaserodDB01079patient_conditionUSOral
CabazitaxelDB06772patient_conditionUSIntravenous
AbirateroneDB05812patient_conditionEUOral
DiclofenacDB00586patient_conditionCanadaTopical
EstriolDB04573patient_conditionItalyVaginal
TreprostinilDB00374patient_condition_associated_withUSOral

+82 more contraindications

DMD (DBCOND0040032)
generic_nameorphan_designationdesignation_statusdesignation_datemarketing_approval_date
delandistrogene moxeparvovec-roklTreatment of Duchenne Muscular Dystrophydesignated_approved2018-06-212024-06-20
vamoroloneTreatment of Duchenne muscular dystrophydesignated_approved2011-12-022023-10-26
golodirsenTreatment of Duchenne muscular dystrophy (DMD)designated_approved2018-05-222019-12-12
BrogidirsenTreatment of Duchenne muscular dystrophydesignated2023-07-31null
Elamipretide HClTreatment of Duchenne Muscular Dystrophydesignated2022-05-10null
(-)-epi-gallocatechin-3-gallateTreatment of Duchenne Muscular Dystrophydesignated_withdrawn2024-03-21null

+50 more designations

Off-label indications, across conditions
conditioncondition_drugbank_iddrugkindcountry
Primary AmyloidosisDBCOND0040057Cyclophosphamideused_in_combination_to_manageUnited Kingdom
Primary AmyloidosisDBCOND0040057Dexamethasoneused_in_combination_to_manageUnited Kingdom
Norwegian scabiesDBCOND0025572Ivermectinused_in_combination_to_treatnull
RhinopharyngitisDBCOND0052141Pseudoephedrineused_in_combination_for_symptomatic_treatment_ofTurkey
Ocular HypertensionDBCOND0074237Pilocarpineused_in_combination_to_treatnull

+1,344 more off-label indications

Questions it answers

  • Which approved drugs could be repositioned into this indication? Landscape and whitespace analysis
  • How crowded is this indication, from preclinical to approved? Landscape and whitespace analysis
  • What's the orphan precedent here before we commit? Target diligence

All figures pulled as of November 2026.

Get answers you can trust, every time.